CDP-choline accumulation in breast and colorectal cancer cells treated with a GSK-3-targeting inhibitor

Su Myat Phyu1 · Chih-Chung Tseng1 · Tim Andrew Davies Smith1

Received: 20 August 2018 / Revised: 1 November 2018 / Accepted: 12 November 2018 / Published online: 16 November 2018
© The Author(s) 2018

Abstract
Purpose Glycogen synthase kinase 3 (GSK3) is a key controlling element of many cellular processes including cell-cycle progression and recent studies suggest that GSK3 is a potential anticancer target. Changes in glucose metabolism associated with GSK3 inhibition may impact on lipid synthesis, whilst lipid metabolites can act as molecular response markers.

Methods Here, SKBr3 breast and HCT8 colorectal cancer cells were treated with the GSK3 inhibitor SB216763, and [14C (U)] glucose and [3H] choline incorporation into lipids was determined. Cell extracts from treated cells were subject to 31P NMR spectroscopy.

Results SB216763 treatment decreased choline incorporation into lipids and caused an accumulation of CDP-choline which was accompanied by decreased conversion of glucose into lipid components.

Conclusion SB216763 profoundly inhibits phospholipid synthesis in cancer cells which demonstrate accumulation of CDP-choline detectable by 31P NMR spectroscopy. Metabolic changes in lipid metabolism present potential response markers to drugs targeting GSK3.

Keywords Glycogen synthase kinase 3 · CDP-choline · 31P nuclear magnetic resonance spectroscopy · Lipid · Glucose · Choline

Introduction
Glycogen synthase kinase 3 (GSK3) is a family of serine/threonine kinases comprising GSK3α and GSK3β which was originally identified as a key controller of metabolism via its inhibitory phosphorylation of glycogen synthase [1]. More recently, GSK3 has been shown to control a broad range of cellular functions through phosphorylation of many target proteins [2]. These functions include cell-cycle progression, energy homeostasis and inflammation [2]. GSK3 activity is constitutively activated and control of its activity is chiefly through inhibitory phosphorylation of serine-9. One major pathway responsible for this inhibition is the PI3K/PDK1/Akt pathway [3] which is frequently up-regulated in cancer and controls glucose metabolism [4]. Abnormal GSK3 activity is associated with several disease states including diabetes, inflammation and cancer [5]. It has been proposed that GSK3 could be a target for anticancer treatments [6] and studies have shown that inhibition of GSK3 activity is associated with suppressed cancer growth, and in breast and colorectal cancer, it can attenuate resistance to anticancer treatments [7]. Inhibition of GSK3 in glioma has been shown to induce cell death preceded by changes in glucose metabolism including reduced glucose content [8].

Cancer is associated with increased phospholipid metabolism due to high demand for membrane synthesis and intracellular signalling. 31P NMR spectroscopy is an analytical technique which facilitates quantitation of phosphorus-containing molecules in cells, tissues and their extracts [9, 10]. The technique is clinically translatable and patient studies of cancer tissue in vivo and subsequent analysis of extracts of the tumour have demonstrated high levels of the phosphatidylcholine metabolite phosphocholine (PCho) [11] which decrease in cancers responding to treatment [12].

As phospholipid synthesis requires intermediates from glucose metabolism, we hypothesised that inhibition of GSK3 may result in changes in phospholipid metabolite content that may be evident in using 31P NMR. To investigate
this, we have subjected chemical extracts from cancer cells treated with growth inhibitory doses of the GSK3 inhibitor SB216763 to $^{31}$P NMR spectroscopy.

**Methods**

**Materials**

Unless otherwise stated, all chemicals were purchased from Sigma-Aldrich (Poole Dorset). Cancer cell lines were purchased from ATCC (LGC Standards, Teddington, UK) and maintained in Dulbecco’s Modified Eagles medium (Gibco, Life Technologies Ltd, UK) supplemented with 10% foetal bovine serum and penicillin (100µU/ml)/streptomycin (100 µg/ml) in 75 cm² tissue culture flasks until confluent. MDA-MB-468 breast cancer cells and HCT-8 colorectal cancer cells were obtained from the American Tissue Culture Collection (ATCC) (LGC standards UK).

**Cytotoxicity assay**

The sensitivity of cancer cells to the GSK3 inhibitor SB216763 was determined using the MTT [(3-(4,5-Dimethylthiazol-2-yl)-2,5-Diphenyltetrazonium Bromide] assay. Briefly, cells were seeded in 96-well plates by adding 100 µl of cells per well at cell densities of 5 × 10⁴ per ml. The cells were left overnight at 37 °C in a CO₂ incubator, and then treated with a range of concentrations of SB216763 (1–200 µM) for 72 h. Cells were then quantified by addition of MTT (0.5 mg/ml in medium) and incubation for 2 h followed by removal of medium and addition of DMSO (200 µl). The absorbance was then measured at 570 nm using a scanning multi-well spectrophotometer (Dynatech MR 5000, Dynatech Laboratories, Chantilly, VA, USA) after 10-s agitation and the readings analysed using Ascent software. $IC_{50}$s were calculated using CompuSyn software (Combosyn, Paramus, NJ, USA).

**$[^{3}H]$-methyl]Choline incorporation assay**

Cells (10⁶) in 5 ml of medium were seeded in eight 25 cm² tissue culture flasks and left overnight in a CO₂ incubator at 37 °C. The cells were then treated for 4, 24 or 72 h with SB216763 (40 µM) after which the medium was removed and fresh media (0.5 ml) containing 37KBq/ml of $[^{3}H]$-methyl choline were added and incubated at 37 °C for 15 min. The cells were then washed 4 x by the rapid rinsing of each flask with ice-cold phosphate-buffered saline (5 ml). The cells were then incubated with medium (1 ml) for 1 h at 37 °C after which the medium was retained for measurement of radioactivity and the cells detached and transferred into a microfuge tube. The cells were pelleted by centrifuging at 400g for 5 min and the supernatant retained for radioactive counting. The cells were then lysed by addition of 0.375 ml of a 1:2 mixture of chloroform and methanol, and periodic agitation on a vortex mixer for 1 h. Then, 0.125 ml of TRIS: HCl buffer (1 mM pH 7.4) and 125 ml of chloroform were added. After shaking the mixture was centrifuged at 10,000g for 10 min and the upper (aqueous phase) and lower (lipid phase) were collected. The cell residue due at the interface was dissolved in 0.5 ml of NaOH (1 M) and after neutralising with HCl (1 M) the protein content in the cell residue determined. The lipid phase was added to scintillation fluid (5 ml). The volume of the aqueous phase was determined and 100 µl was added to a scintillation vial containing 5 ml of scintillation fluid. A further 100 µl was subject to phosphate precipitation [13] by addition of 100 µl each of Ba(OH)₂ (0.3 M) and ZnSO₄ (5%) followed by vigorous shaking for 5 min. The precipitate was pelleted and 150 µl was added to a scintillation vial with 5 ml of scintillation fluid.

**[U-$^{14}$C] Glucose incorporation into lipids and glycerol assay**

As described previously [14], cells were prepared as for "$[^{3}H]$ choline incorporation assay' and cells were incubated with [U-$^{14}$C-U] glucose in medium (0.5 ml) (3.7 KBq/ml) for 2 h. The cells were then washed 4 x with ice-cold PBS, detached with trypsin and transferred to a 1-ml microfuge tube and pelleted by centrifugation at 400g for 5 min. The supernatant was removed and radioactivity was determined by adding to a scintillation vial containing 5 ml of scintillation fluid and measuring in a scintillation counter. The pelleted cells were suspended in PBS (1 ml), pelleted and radioactivity determined in the wash. The lipid and aqueous components were then fractionated as described for "$[^{3}H$-methyl] choline incorporation assay'. The lipid phase volume was measured and radioactivity determined in a 50-µl sample. The remainder was dried at 37 °C and the complex glycerides were subject to saponification by dissolving in a 1:10 water: ethanol solution of KOH (10 M) and heating to 70 °C for 20 min [15]. The glycero and fatty acids were separated by fractionation into aqueous and lipid phases as described above [16] and the radioactivity was determined in the two phases.

**NMR sample preparation and $^{31}$P NMR spectroscopy**

Cells (2 × 10⁶) were seeded in each of four 75 cm² tissue culture flasks and allowed to achieve 80% confluence in a CO₂ incubator at 37 °C. Media were then removed and 10 ml of medium containing SB216763 (40 µM) was added to 2 flasks and 10 ml of medium containing the same volume of DMSO (vehicle—typically 10 µl) was added to the two
control flasks. After the respective treatment period (24 or 72 h), the cells were detached with trypsin (5 ml) and the trypsin neutralised with ice-cold medium decanted into 15 ml tubes and placed on ice for 10 min. The cells were then centrifuged at 400g for 5 min and after removal of the medium, the cells were suspended in ice-cold saline (0.9%) (1 ml) transferred to a microfuge tube, centrifuged at 400g for 5 min. This step was repeated twice to remove extracellular phosphate. The pellet was suspended in 0.375 ml of chloroform: methanol (1:2) and 10 µl EDTA (10 mM) and 20 µl of 1-aminopropyl phosphoric acid (0.3 µmol) as an internal standard and left on ice for 1 h with occasional mixing. The aqueous and lipid phases were then separated by addition of 125 ml each of chloroform and TRIS buffer (10 mM pH7.4) followed by centrifugation at 12,000g for 10 min. The aqueous phase was then made up to 0.6 ml by addition of 60 µl of D2O and water. The NMR measurement was carried out on a Bruker ADVANCE III 400 NMR spectrometer (400 MHz) operating at 161.98 MHz for 31P with continuous broadband 1H decoupling (WALTZ16) and at least 20,000 acquisitions. The parameters for each acquisition were: acquisition time 1.258 s; relaxation delay 2 s (inter-pulse time = 3.258 s) (metabolite concentrations were the same when spectra were obtained with a 1-s relaxation delay, indicating that metabolites were fully relaxed in this solvent system after a 1-s delay [17]); pulse angle 45°. All acquisitions were made at 25 °C. Metabolite concentrations were determined by comparison with the internal standard (0.3 µmol) signal at 11.8 ppm. The reference for 0 ppm is 85% H3PO4.

**Glycogen synthesis**

Cells were seeded (10^6 per flask) in 25 cm² flasks, then treated in triplicate when 70% confluent with SB216763. Glycogen synthesis was assessed by measuring conversion of [14C-(U)]-glucose into [14C-(U)]-glycogen in the cells treated with SB216763 for 4 h. The cells were incubated with 0.25 ml of [14C]-glucose (55 KBq/ml) for 90 min, washed rapidly with ice-cold PBS, then dissolved in 150 µl of KOH 20% (w/v) for 1 h at 70 °C. Glycogen was precipitated by addition of 50 µl of glycogen (2 mg/ml) as carrier followed by 0.5 ml of ice-cold ethanol and leaving for 2 h at ~ 20 °C. After centrifugation at 10,000g for 10 min, the supernatant was removed, and the precipitated glycogen dissolved in 150 µl of hot water, and transferred to scintillation vials containing 5 ml of scintillation fluid. The radioactive glycogen value was normalised to protein content carried out on 50 µl of the supernatant after neutralising the KOH with HCl (1 M).

**Statistics**

Data are expressed as mean ± SEM and statistical differences determined by the student t test and values expressed as (t = x, p < y), where t values and probability are unitless values. All experiments were carried out 2 or more times.

**Results**

**Cancer cell sensitivity to SB216763**

The effect of 3-day treatment with different concentrations of SB216763 (0–100 µM) on the growth of SKBr3 cells is shown in Fig. 1. Subsequent experiments were carried out using 40 µM concentrations of SB216763.

**Changes in 31P NMR detectable metabolites by SB216763 treatment**

Control cells and cells treated with SB216763 were subject to 31P NMR spectroscopy. Figure 2a–c shows an example of 31P NMR spectra from a chemical extract of control and SB216763-treated SKBr3 cells. A peak corresponding with CDP-choline which was at very low levels or undetectable levels in the controls was present at significantly higher levels (p < 0.05) in the cells treated with SB216763 for 24 h [control 0.002 µmol/mg protein (± 0.001), SB-treated 0.012 µmol/mg protein (± 0.003)] and was also present in cells treated for 72 h (Fig. 2c). The CDP-choline peak was also present in HCT8 colorectal cancer cells treated with SB216763 for 24 h (Fig. 2e) but not controls (Fig. 2d). CDP-choline is formed by reaction of phosphocholine (PCho) with cytidine triphosphate (CTP). The content of PCho was similar in control [0.1 (± 0.012) µmol/mg protein] and SB-treated [0.085 (± 0.03) umole/mg protein] SKBr3 cells. The next step is the reaction of CDP-choline with diacylglycerol (DAG). As DAG can be formed, de novo, from the glycolysis

---

**Fig. 1 Relative growth of SKBr3 cells treated with doses of 0–100 µM SB216763 for 3 days**

© Springer
intermediate glycerol 3 phosphate, the effect of SB216763 on carbon flux from glucose was examined.

Flux of $^{14}$C from glucose to lipids

Glucose incorporation into lipids was determined in SKBr3 and HCT8 cells. Figure 3 shows the incorporation of glucose into lipid (Fig. 3a) and fatty acids (Fig. 3b) and glycerol.
(Fig. 3c) in cells treated with SB216763 relative to untreated cells. In both cell lines, the incorporation of $^{14}$C- from glucose into lipid was decreased (SKBr3: $t = 11.7$, $p < 0.001$; HCT8 $t = 8.2$, $p < 0.001$) and this decrease was found to be in both the glycerol (derived from dihydroxyacetone phosphate during glycolysis) (SKBr3: $t = 3.1$, $p < 0.01$; HCT8: $t = 7.3$, $p < 0.001$) and fatty acid (derived from intermediates of the Krebs cycle) (SKBr3: $t = 11$, $p < 0.001$; HCT8: $t = 9.3$, $p < 0.001$) fractions.

Effect of SB216763 treatment on choline uptake and incorporation into lipids

Figure 4 shows the total uptake (a and b) and proportion of phosphorylated $[^3]$H-methyl choline (c and d) and the incorporation into lipids (e and f) by SKBr3 and HCT8 cells treated with SB216763 for 4, 24 and 72 h compared with untreated cells. In each cell line, $[^3]$H-methyl choline incorporation into lipids was decreased after 4 h (HCT8: $t = 5.6$, $p < 0.001$; SKBr3: $t = 16$, $p < 0.001$), 24 h (HCT8: $t = 5.8$, $p < 0.001$; $t = 3.5$, $p < 0.01$) and 72 h (HCT8: $t = 6.6$, $p < 0.001$; SKBr3: $t = 28$, $p < 0.001$) treatment with SB216763. The uptake of $[^3]$H-methyl choline was unaffected by treatment of cells with SB216763 by each cell line at each time point except HCT8 cells at 72 h which showed a significant ($t = 3.3$, $p < 0.05$) increase in incorporation.

The proportion of $[^3]$H-methyl choline that was phosphorylated was unchanged in cells treated for 4 h, decreased in HCT8 ($t = 4.1$, $p < 0.01$) and SKBr3 ($t = 18$, $p < 0.001$) cells treated for 24 h and unchanged in cells treated for 72 h with SB216763.

The effect of treatment with SB216763 on glycogen synthesis cells is shown in Fig. 5. Conversion of $[^1]$C glucose into $[^1]$C glycogen was found to be increased by HCT8 cells treated with SB216763.
Discussion

De novo synthesis from glucose is the major route for the formation of diacylglycerol (DAG) for metabolic purposes [18]. The flux of carbon from glucose into anabolic pathways responsible for the synthesis of phospholipids is facilitated in cancer cells by decreased oxidative phosphorylation and increased glycolysis resulting in an increased supply of acetyl CoA for glycerol and fatty acid synthesis [19].

Phospholipid metabolism is crucial for proliferation as it provides cell membrane and intracellular signalling components [20]. Phosphatidylcholine (PtdCho) is an abundant phospholipid in mammalian cell membranes [21] and is an important source of intracellular signalling pathway intermediates [22]. Inhibition of PtdCho synthesis in mammalian cells including cancer has been shown to induce cell death [23]. The de novo synthesis of PtdCho occurs by the CDP-choline pathway. Choline, taken into cells by the choline transporter (ChT), is phosphorylated to phosphocholine (PCho) by choline kinase. The enzyme CTP phosphocholine cytidyltransferase (CT) converts Cytidine triphosphate (CTP) and PCho into CDP-choline. The enzyme CDP-choline:1,2-diacylglycerolcholinephosphotransferase (CPT) then catalyses the conversion of CDP-choline and diacylglycerol into PtdCho.

Breast cancer cells were found to be sensitive to the growth inhibitory effect of the GSK3 inhibitor SB216763 in agreement with others [24]. Zeng et al. [25] have shown that overexpression of GSK3β in non-small-cell lung cancer is associated with poor prognosis and its inhibition decreased cell proliferation by causing cell-cycle arrest in G1/S. They suggested that GSK3β acts as a tumour promoter and a potential therapeutic target. Evidence from work on MCF7 breast cancer cells suggests that the growth inhibitory effect of GSK3β inhibition results subsequent decrease in cyclin D1 expression [26].

Treatment of SKBr3 and HCT8 cells with S216763 decreased the flux of carbon from glucose to lipids and the incorporation of choline into lipids which could be attributed to increased formation of glycogen from glucose associated with GSK3β inhibition [27]. In agreement with these findings Park et al. [28] has recently shown that inhibition of GSK3β in colorectal cancer cells resulted in decreased fatty acid synthesis.

31P NMR studies were carried out on cells treated for up to 72 h with SB216763 in common with previous work [29]. Interestingly, CDP-choline formation is considered as the rate-limiting step for PtdCho formation; so, its build up is unusual further suggesting that the decrease in PtdCho in cells treated with SB216763 formation is a consequence of inadequate substrate (DAG) for the final CTP-catalysed reaction of CDP-choline and diacylglycerol into PtdCho.

Fig. 3 Incorporation of 14C into lipid-soluble metabolites (fraction of total [14C] glucose uptake) (a) and fraction of lipid-soluble 14C incorporated into Fatty acids (b) and glycerol (c) untreated and SB216763-treated SKBr3 and HCT8 cells. Cells were incubated with [14C (U)] glucose for 2 h then washed rapidly with ice-cold PBS. Cells were fractionated into aqueous and lipid soluble components and 14C-associated with the lipid fraction determined (a). The lipid fraction was subject to saponification to release the fatty acids from glycerol and then fractionated into lipid (fatty acids) (control (grey) SB216763-treated (grey)) and aqueous (glycerol) (control (white) SB216763-treated (grey)) and 14C-associated with the two fractions determined.
Previous studies [12, 31] have shown that the content of PMEs decrease in tumours responding to treatment and that this may be a useful early response indicator. Although treatment of cancer cells with SB216763 was not accompanied by changes in the concentration of PCho, the appearance of the CDP-choline peak in the $^{31}$P NMR spectrum suggests that this might be a useful early indicator of response to drugs targeting GSKβ. However, early expectations that in vivo $^{31}$P NMR spectroscopy could be used in the clinic have not yet materialised, mainly due to the relative insensitivity of the technique compared with, for example $[^{18}$F]-FDG-PET. A further problem with the quantification of the CDP-choline resonance in in vivo spectra is its chemical shift, which is close to that of nucleotide adenine dinucleotide (NAD(H)) resonance with which it most likely forms a composite peak.

Radioactive counts normalised to mg protein and expressed as a percentage of untreated values (% control). Statistically significant differences indicated by asterisk (*$p$<0.05; **$p$<0.01; ***$p$<0.001)

Fig. 4 [3H-methyl] choline incorporation by untreated (white) and SB216763-treated (grey) SKBr3 and HCT8 cells. Total uptake (a, b), phosphorylated fraction (c, d) and lipid fraction (e, f). Units: Radioactive counts normalised to mg protein and expressed as a percentage of untreated values (% control). Statistically significant differences indicated by asterisk (*$p$<0.05; **$p$<0.01; ***$p$<0.001)

Fig. 5 Incorporation of $[^{14}$C] into glycogen by control and SB216763-treated HCT8 cells incubated with $[^{14}$C] glucose

Previous studies [12, 31] have shown that the content of PMEs decrease in tumours responding to treatment and that this may be a useful early response indicator. Although treatment of cancer cells with SB216763 was not accompanied by changes in the concentration of PCho, the appearance of the CDP-choline peak in the $^{31}$P NMR spectrum suggests that this might be a useful early indicator of response to drugs targeting GSKβ. However, early expectations that in vivo $^{31}$P NMR spectroscopy could be used in the clinic have not yet materialised, mainly due to the relative insensitivity of the technique compared with, for example $[^{18}$F]-FDG-PET. A further problem with the quantification of the CDP-choline resonance in in vivo spectra is its chemical shift, which is close to that of nucleotide adenine dinucleotide (NAD(H)) resonance with which it most likely forms a composite peak. On a more positive note, instruments with higher magnetic
field strengths and proton decoupling are improving peak resolution [32].

In conclusion, treatment of cancer cells with the GSK3 inhibitor SB216763 results in decreased transfer of carbon from glucose to lipids, cellular accumulation of CDP-choline and decreased incorporation of choline into PtdCho.

Acknowledgements Funding from the University of Aberdeen Development Trust is gratefully acknowledged. Professor Zanda is gratefully acknowledged for the use of his NMR system.

Author contributions Study conception and design: TADS and SMP; Acquisition of data: CCT and SMP; Analysis and interpretation of data: all authors; Drafting of manuscript: TADS and SMP; Critical revision: all authors.

Compliance with ethical standards

Conflict of interest The authors declare that they have no conflict of interest.

Ethical approval This article does not contain any studies with human participants or animals performed by any of the authors.

Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

References

1. Embi N, Rylatt DB, Cohen P (1980) Glycogen synthase kinase-3 from rabbit skeletal muscle. Separation from cyclic-AMP-dependent protein kinase and phosphorylase kinase. Eur J Biochem 107:519–527
2. Liu X, Yao Z (2016) Chronic over-nutrition and dysregulation of glycolysis and lipid metabolism in cancer cells. Mol Cell Biol 24:730–740
3. Majewski N, Nogueira V, Robet RB et al (2004) Akt inhibits apoptosis downstream of BID cleavage via a glucose-dependent mechanism involving mitochondrial hexokinases. Mol Cell Biol 24:730–740
4. Fleming IN, Andriu A, Smith TAD (2014) Early changes in [18F] FDG incorporation by breast cancer cells treated with trastuzumab in normoxic conditions: role of the Akt-pathway, glucose transport and HIF-1α. Breast Cancer Res Treat 144:241–248
5. Eldar-Finkelman H (2002) Glycogen synthase kinase 3: an emerging therapeutic target. Trends Mol Med 8:126–132
6. Mcruibrey JA, Steelman LS, Bertrand FE et al (2014) GSK3 as potential target for therapeutic intervention in cancer. Oncotarget 5:2881–2911
7. Domoto T, Pyko IY, Furuta T et al (2016) Glycogen synthase kinase-3 is a pivotal mediator of cancer invasion and resistance to therapy. Cancer Sci 107:1363–1372
8. Kotliarova S, Pastorino S, Kovell LC et al (2008) Fine, Glycogen synthase kinase-3 inhibition induces glioma cell death through c-MYC, nuclear factor-kappa B, and glucose regulation. Cancer Res 68:6643–6651
9. Glunde K, Penet MF, Jiang L et al (2005) Choline metabolism-based molecular diagnosis of cancer: an update. Expert Rev Mol Diagn 15:735–747
10. Podo F, Saradanelle E, Iorio R et al (2007) Abnormal choline phospholipid metabolism in breast and ovary cancer: molecular bases for noninvasive imaging approaches. Curr Med Imaging Rev 3:123–137
11. Smith TAD, Glaholm J, Leach KO et al (1991) A comparison of in vivo and in vitro 31P NMR spectra from human breast tumours: variations in phosphorus metabolism. Br J Cancer 63:514–516
12. Leach MO, Verrill MR, Glaholm J et al (1998) Measurements of Human Breast Cancer using Magnetic Resonance Spectroscopy: a review of clinical measurement and a report of localized [39]P measurements of response to treatment. NMR Biomed 11:314–340
13. Kletzen R, Perdue JF (1974) Sugar transport in chick embryo fibroblasts. J Biol Chem 249:3366–3374
14. Smith TAD, Phyu SM (2016) Metformin decouples phospholipid metabolism in breast cancer cells. PLoS One 11:e0151179
15. Hosotani K, Kitagawa M (2003) Improved simultaneous determination method of b-carotene and retinol with saponification in human serum and rat liver. J Chromatogr B 791:305–313
16. Tan HM, Aziz ARA, Arouka MK (2013) Glycerol production and its applications as a raw material: a review. Renew Sustain Energy Rev 27:118–127
17. Phyu SM, Tseng CC, Fleming IN, Smith TAD (2016) Probing the PI3K/Akt/mTOR pathway using 31P-NMR spectroscopy: routes to glycogen synthase kinase-3. Sci Rep 6:36544
18. Carrasso S, Merida I (2007) Diacylglycerol, when simplicity becomes complex. Trends Biochem Sci 32:27–36
19. Ridgway ND (2015) The role of phosphatidylcholine and choline metabolites to cell proliferation and survival. Crit Rev Biochem Mol Biol 48:20–38
20. Arluckas SP, Popov AV, Delikatny EJ (2016) Choline kinase alpha-Putting the ChoK-hold on tumor metabolism. Prog Lipid Res 63:28–40
21. Ide Y, Waki M, Hayasaka T et al (2013) Human breast cancer tissues contain abundant phosphatidylcholine(36:1) with high stearoyl-CoA desaturase-1 expression. PLoS One 8:e61204
22. Sovadinaova I, Babica P, Boeke H et al (2015) Phosphatidylcholine-specific PLC-induced dysregulation of gap junctions, a robust cellular response to environmental toxicants, and prevention by resveratrol in a rat liver cell model. PLoS One 10:e0124454
23. Cui Z, Houweling M (2002) Phosphatidylcholine and cell death. Biochim Biophys Acta 1585:87–96
24. Trnaki D, Sabol M, Gojevic A et al (2015) GSK3 beta and Gli3 play a role in activation of Hedgehog-Gli pathway in human colon cancer—targeting GSK3 beta downregulates the signaling pathway and reduces cell proliferation. Biochim Biophys Acta 1852:2574–2584
25. Zeng J, Liu D, Qiu ZX et al (2014) GSK3 beta overexpression indicates poor prognosis and its inhibition reduces cell proliferation and survival of non-small cell lung cancer. PLoS One 9:e91231
26. Kim HM, Kim CS, Lee JH et al (2013) CG0009, a novel glycosgen synthase kinase 3 inhibitor, induces cell death through cyclin d1 depletion in breast cancer cells. PLoS One 8:e60383Cells
27. Ha DT, Trinh NT, Hien TT et al (2010) Selected compounds from glucose to lipids, cellular accumulation of CDP-choline and decreased incorporation of choline into PtdCho.
28. Park GB, Chung YH, Gong JH et al (2016) GSK-3 beta-mediated fatty acid synthesis enhances epithelial to mesenchymal transition of TLR4-activated colorectal cancer cells through regulation of TAP63. Int J Oncol 49:2163–2172
29. Al-saffar NMS, Jackson E, Raynaud FL et al (2010) The phosphoinositide 3-kinase inhibitor PI-103 downregulates choline kinase
a leading to phosphocholine and total choline decrease detected by magnetic resonance spectroscopy. Cancer Res 70:5507–5517
30. Anthony ML, Zhao M, Brindle KM (1999) Inhibition of phosphatidylcholine biosynthesis following induction of apoptosis in HL-60 cells. J Biol Chem 274:19686–19692
31. Al-Saeedi F, Welch AE, Smith TAD (2005) [methyl-3H] choline incorporation into MCF7 tumour cells: correlation with proliferation. Eur J Nucl Med 32:660–667
32. Lagemaat MW, Maas MC, Vos EK et al (2015) 31P MR spectroscopic imaging of the human prostate at 7T: T1 relaxation times, nuclear overhauser effect, and spectral characterization. Magn Resonan Med 73:909–920